Arcticzymes Technologies ASA
OSE:AZT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Arcticzymes Technologies ASA
Depreciation & Amortization
Arcticzymes Technologies ASA
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Depreciation & Amortization
-kr9.2m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-12%
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Depreciation & Amortization
-kr39.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Depreciation & Amortization
-kr915k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Depreciation & Amortization
-$2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Depreciation & Amortization
-kr23k
|
CAGR 3-Years
74%
|
CAGR 5-Years
59%
|
CAGR 10-Years
3%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Depreciation & Amortization
-kr20.9m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-51%
|
|
Arcticzymes Technologies ASA
Glance View
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms. The company went IPO on 2005-11-04. The firm focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.
See Also
What is Arcticzymes Technologies ASA's Depreciation & Amortization?
Depreciation & Amortization
-9.2m
NOK
Based on the financial report for Dec 31, 2025, Arcticzymes Technologies ASA's Depreciation & Amortization amounts to -9.2m NOK.
What is Arcticzymes Technologies ASA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-12%
Over the last year, the Depreciation & Amortization growth was -39%. The average annual Depreciation & Amortization growth rates for Arcticzymes Technologies ASA have been -22% over the past three years , -22% over the past five years , and -12% over the past ten years .
